AUS
NZ
UK
CA
USA
IND
Highlights
ResMed (RMD) operates in over 140 countries
Focuses on CPAP therapy and SaaS for out-of-hospital care
Listed on both NYSE and ASX, with US reporting standards
ResMed (ASX:RMD), a global player in the medical equipment and digital health space, continues to attract attention due to its strong presence in sleep and respiratory care. With a global footprint spanning over 140 countries and a team of more than professionals, the company has positioned itself at the intersection of advanced healthcare devices and smart software solutions. Notably, ResMed is part of the ASX 100, which highlights its significance among Australia’s top listed companies by market capitalisation.
Dual Business Model Strengthens Global Impact
ResMed operates through two key business divisions: Sleep and Respiratory Care, and Software as a Service (SaaS). The Sleep and Respiratory Care unit offers cloud-connected devices including continuous positive airway pressure (CPAP) machines, which are designed to support individuals suffering from obstructive sleep apnea (OSA). These machines are not only used for nightly treatment but also serve critical roles in non-invasive and invasive ventilation therapy for patients who require life-support care.
The SaaS division complements the hardware offerings by focusing on software platforms used in the durable medical equipment (DME) and home medical equipment (HME) sector. These solutions help providers manage out-of-hospital care more efficiently through scheduling, billing, and patient communication tools. By bridging hardware with intelligent data services, ResMed ensures a streamlined experience for healthcare providers and improved outcomes for patients.
Global Presence with a Local Market Identity
While ResMed has its operational headquarters in the United States, its origins trace back to Australia. This has allowed the company to maintain a dual-market presence, being listed on both the New York Stock Exchange and the Australian Securities Exchange. Due to its primary listing being in the US, ResMed follows American reporting formats for its market disclosures, making its financial reporting slightly different from many other Australian-listed entities.
Despite its international structure, ResMed remains a significant component of the Australian share market landscape. Its inclusion in the ASX 100 reinforces its relevance to local market watchers. This dual-market strategy enables the company to leverage growth across continents, while also maintaining its legacy in the Australian healthcare space.
Technology-Driven Healthcare Outcomes
One of ResMed’s major strengths lies in its integration of data-driven insights into clinical care. By combining cloud-enabled hardware—like masks, humidifiers, and ventilators—with its SaaS platforms, ResMed is transforming how care is delivered outside the hospital setting. This combination not only supports better patient monitoring and outcomes but also contributes to reducing healthcare costs over time.
Its systems allow healthcare professionals to remotely access data, track patient compliance, and optimise treatment plans, all while reducing the administrative burden typically associated with home care services. These advancements make ResMed a notable contributor to the growing digital transformation in healthcare.
